Key Investor Signals
Reached more than 100 healthcare professionals
AIMA’s live platform states that more than 100 professionals use its service, spanning nutrition, medical practice, sports centres and longevity clinics.
Launched a clinician-facing microbiota test suite
The current catalogue offers bacterial, expanded and shotgun sequencing options, with sample logistics and editable AI-assisted reporting integrated into one service.
Combined microbiology and genomic data experience
Co-founders bring prior work at microbiome sequencing provider Microomics and genomics company Binartis, combining laboratory-facing and software experience.
Other Positive Signals
- Linked more than 1,000 scientific articles within its clinician-support resources.
- Appeared in the GoDigital Pitch lineup as a precision-health platform.
Team
Alfredo García Martínez
CEO and Co-founder
- Worked in sales and field applications at microbiome sequencing provider Microomics Systems from 2023 to 2026.
- Advised EDYPRO on isolating and validating microbial strains, developing R&D services and securing project funding.
- Worked on clinical and pharmacogenomic interpretation of sequencing data, including genomic report preparation.
Juan Carlos Marco Gil
CTO and Co-founder
- Worked as R&D director and software engineer at Binartis Genomics, applying data tools to genomic analysis.
- Built machine-learning models and deployment pipelines at Idrica from 2022 to 2024, including laboratory-data applications.
- Worked as a data scientist at Keepler Data Tech, bringing experience in enterprise AI, data and cloud technology.
Product
AIMA offers a range of gut microbiota tests through healthcare professionals. A home-collected stool sample is analysed in a laboratory, then sequencing results and a patient questionnaire feed a platform for clinical review, interpretation and follow-up.
Choosing the depth of analysis
The catalogue ranges from bacterial profiling to broader shotgun metagenomics covering bacteria, archaea, fungi, viruses and parasites. A separate metabolomics option adds measurements of biological compounds to the microbial profile.
Reviewing AI-assisted findings
AIMA Care generates an interpretation using the laboratory results and patient questionnaire. The clinician reviews, edits and contextualizes the findings before producing a patient report under the clinic’s own branding.
Managing home sampling and follow-up
Patients receive a stool-sampling kit at home and arrange collection when it is ready. AIMA handles sample logistics and delivers results through its platform, where clinicians can compare profiles across follow-up tests.
Market Overview
Functional gastrointestinal disorders affect a substantial share of adults worldwide, creating a broad pool of people seeking help for IBS, constipation, dyspepsia and related symptoms. Rome Foundation data show 40.3% of adults in a multinational internet survey met criteria for at least one functional gut disorder.
That symptom burden supports recurring demand across gastroenterology, nutrition and primary-care settings for tools that help characterize persistent digestive problems and guide follow-up. AIMA targets this clinician-led segment with microbiome testing and interpretation integrated into ongoing assessment and dietary-management workflows.
In the Rome global internet survey, 40.3% of adults met criteria for at least one functional gut disorder.
Rome IV criteria identified IBS in 4.1% of adults in the multinational internet survey.
Functional constipation affected 11.7% of respondents in the cited Rome global survey.
Functional dyspepsia affected 7.2% of respondents in the cited Rome global survey.
Comparable Outcomes
Ambry Genetics
Offered clinical genetic tests that identified inherited disease risks and guided personalized care decisions. Tempus completed the $600 million acquisition in February 2025, with $375 million cash and $225 million in stock.
Thorne HealthTech
Sold at-home biomarker tests alongside supplements, using results to personalize recommendations. L Catterton completed the acquisition in October 2023 after agreeing a transaction valued at approximately $680 million.
Interested in More Startups Like AIMA Biotech?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.